The Journal of Clinical Psychiatry

Supplementary Material

- Article Title: Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Authors: Emma Sampson, BHlthSc(Honours); Natalie T. Mills, MBBS, PhD; Hikaru Hori, MD, PhD; Kathrin Schwarte, MTLA; Christa Hohoff, PhD; K. Oliver Schubert, MD, PhD; Scott R. Clark, MBBS, PhD; Célia Fourrier, PhD; and Bernhard T. Baune, MD, PhD

DOI Number: 10.4088/JCP.23m14829

LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE


- 1. Figure 1 Graphs of Change of Individual Cognitive Outcome Measures Over Time for Vortioxetine + Placebo and Vortioxetine + Celecoxib Participants
- 2. <u>Table 1</u> Change in THINC-it Individual Cognition Objective Measure Estimates Over Time (Adjusted Model) for Vortioxetine + Placebo and Vortioxetine + Celecoxib Treatment Groups in the PREDDICT Study
- 3. Appendix 1 Summary of Supplementary Results

DISCLAIMER

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Figure 1: Graphs of change of individual cognitive outcome measures over time for vortioxetine +

placebo and vortioxetine + celecoxib participants



Plots of the mean of vortioxetine + placebo and vortioxetine + celecoxib scores at baseline, week 2, and week 6 time points for THINC-it tasks **a** Spotter number correct, **b** Spotter mean response time, **c** Symbol Check number correct, **d** Symbol Check mean response time, **e** Codebreaker number correct, **f** Codebreaker mean response time, **g** Trails number of errors, **h** Trails total response time, **i** PDQ-5-D score. Error bars represent 95% confidence interval.

Supplementary Table 1: Change in THINC-it individual cognition objective measure estimates over time (adjusted model) for Vortioxetine + Placebo and Vortioxetine + Celecoxib treatment groups in the PREDDICT study

			SMD (95% CI) cha	Estimate (95% CI) ange (baseline to week 6)	p value
		Time by treatment			0.075
		group interaction			0.875
	number	Vortioxetine +	-0.020		
	correct ^a	Placebo	(-0.403, 0.363)	0.03 (-0.64, 0.69)	0.935
THINC-it		Vortioxetine +	-0.057		
Spotter		Celecoxib	(-0.436, 0.322)	-0.12 (-0.77, 0.54)	0.72
Choice		Time by treatment	(0.100,0.022)		
reaction time		group interaction			0.137
(CRT)	moon rosponso	Vortioxetine +	-0.440	-67.36	
	mean response				<0.00
	time	Placebo	(-0.827, -0.052)	(-98.49, -36.23)	
		Vortioxetine +	-0.576	-83.48	<0.00
		Celecoxib	(-0.961, -0.187)	(-114.16, -52.79)	
		Time by treatment			0.937
	number	group interaction			0.007
	correct ^a	Vortioxetine +	0.424 (0.035, 0.810)	3.85 (1.87, 5.83)	<0.00
	correct	Placebo	0.424 (0.055, 0.810)	3.85 (1.87, 5.85)	<0.00
THINC-it		Vortioxetine +		4.34 (2.39, 6.29)	<0.00
Symbol		Celecoxib	0.438 (0.053, 0.821)	4.34 (2.39, 6.29)	<0.00
Check		Time by treatment			0.72
N-back		, group interaction			0.723
	mean response	Vortioxetine +	-0.405	-84.70	
	time	Placebo	(-0.791, -0.017)	(-129.40, -40.01)	<0.00
	time	Vortioxetine +	-0.466	-110.46	
		Celecoxib	(-0.850, -0.080)	(-154.50, -66.42)	<0.00
		Time by treatment	(-0.850, -0.080)	(-134.30, -00.42)	
					0.322
	number	group interaction			
	correct ^a	Vortioxetine +	0.389 (0.002, 0.775)	5.82 (2.89, 8.76)	<0.00
THINC-it		Placebo			
Codebreaker		Vortioxetine +	0.468 (0.082, 0.851)	7.46 (4.57, 10.35)	<0.00
Digit Symbol		Celecoxib			
Substitution		Time by treatment			0.222
Test (DSST) THINC-it		group interaction			
	mean response	Vortioxetine +	-0.244	-226.32	0.07
	time	Placebo	(-0.628, 0.142)	(-479.34, 26.71)	0.07
		Vortioxetine +	-0.341	-418.67	0.00
		Celecoxib	(-0.722, 0.042)	(-668.16 <i>,</i> -169.18)	0.00
		Time by treatment			0.75
		group interaction			0.75
	number of	Vortioxetine +	-0.327		0.05
	errors	Placebo	(-0.712, 0.059)	-0.70 (-1.41, 0.00)	0.05
		Vortioxetine +	-0.178	/	
Frails		Celecoxib	(-0.560, 0.204)	-0.47 (-1.17, 0.23)	0.18
Trail making		Time by treatment	(,		
test part B		group interaction			0.679
(TMT-B)	total response	Vortioxetine +	-0.560	-5.54	
	total response	Placebo	-0.560 (-0.949 <i>,</i> -0.168)		<0.00
	time			(-8.27, -2.81)	
		Vortioxetine +	-0.377	-3.95	0.00
	ect" measures have	Celecoxib	(-0.761, 0.008)	(-6.65, -1.25)	

^a "number correct" measures have opposite directionality to all others, where a higher score indicates better performance. "Time" variable includes baseline, week 2 and week 6 observations for composite scores. Estimates are differences in means. P values refer to the difference between baseline and week 6. Covariates include participant age, sex, and education level. SMD calculated using package MBESS³³ where Group 1 = week 6 and Group 2 = baseline. Abbreviations: CI = confidence interval, SMD = standard mean difference.

Appendix 1: Summary of supplementary results

The majority of the individual THINC-it cognition measures showed a significant change between baseline and week 6. The directionality of each significant change indicates improvement in performance. Magnitudes of the significant changes over the RCT ranged from small (smallest SMD = -0.341 [DSST mean response time, vortioxetine + celecoxib group]) to medium (largest SMD = -0.576 [CRT mean response time, vortioxetine + celecoxib group].